Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...
The majority of other information websites display prices from a single source, most of the time from one retail broker-dealer. At FXStreet, traders get interbank rates coming from a systematic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback